Volara Home Care Oxygen Systems May Fail to Provide Sufficient Oxygen and Could Cause Lung Damage, FDA Warns

Baxter and the FDA warn the systems could cause overexpansion of the lungs, leading to lung damage and oxygen deficiency.

Federal health officials indicate that certain Volara home care oxygen systems have the potential to malfunction, resulting in a lack of oxygen delivery and an increased risk of lung tissue damage for users.

The FDA issued the Volara home oxygen system warning on June 2, recommending patients to stop using the ventilators if they experience signs of respiratory distress, and to seek immediate medical attention if the symptoms do not subside.

To date, an official Volara oxygen system recall has not been issued, however the FDA been notified of one injury report of a patient experiencing oxygen desaturation while using the Volara device in a home care environment.

The Volara Systems are used for Oscillation and Lung Expansion (OLE) therapy and are designed to be used in the home setting to provide alternating cycles of Continuous Positive Expiratory Pressure (CPEP) and Continuous High Frequency Oscillation (CHFO), combined with aerosol delivery.

According to the warning, when the Volara system is used in line with a ventilator, the device can allow an overexpansion of the lungs that may result in oxygen desaturation, which is a condition that causes a dangerous decrease in oxygen levels. In this event, users could experience signs of respiratory distress including increased breathing rate, wheezing, bluish color around the mouth, inside the lips or in the fingernails and changes in alertness.

Following a report of a patient suffering oxygen desaturation after using the Valora System, Baxter International Inc. issued an Urgent Medical Device Correction on June 1, warning patients to immediately stop using the devices if they experience symptoms of respiratory distress.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

The warning involves Volara System with model numbers PVL1HCBA, M08594, and M08594A with in-line ventilator adaptor (M07937 MODULE, OPTIMUS HANDSET 2) or Volara Patient Circuit Kit (M08473 OPTIMUS OLE AC PAT.CIRCUIT KIT that include M07937).

Baxter announced it will be releasing an update to the Instructions For Use (IFU) manual to help ensure correct usage of the device. Once the updated IFU is available, Baxter indicates it will contact patients to arrange for a trainer to conduct a home visit to provide additional training.

Customers with additional questions or concerns regarding their Volara systems are being encouraged to contact Hillrom Customer Service Support at 800-426-4224 or Baxter Product Surveillance at 800-437-5176.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

First Gardasil Lawsuit Set For Trial To Begin October 7th in California State Court
First Gardasil Lawsuit Set For Trial To Begin October 7th in California State Court (Posted today)

The first Gardasil lawsuit will go to trial in California state court in October, as a group of cases at the federal level continue to be developed for future bellwether trials that are unlikely to begin until late 2025 or early 2026.

Tepezza Settlement Talks For Hearing Loss Claims Will Commence Next Month
Tepezza Settlement Talks For Hearing Loss Claims Will Commence Next Month (Posted today)

Parties have been directed to meet quarterly for mediation sessions, which will explore the potential for Tepezza hearing loss settlements, as the talks leading up to the first bellwether trials, slated to begin in March 2026.

Judge Allows New Ozempic, Wegovy Lawsuits To Be Directly Filed in Federal MDL
Judge Allows New Ozempic, Wegovy Lawsuits To Be Directly Filed in Federal MDL (Posted yesterday)

A federal judge is allowing those presenting Ozempic, Wegovy and Mounjaro lawsuits to file them directly with the MDL court to speed up the process of preparing the cases for potential future bellwether trials.